Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women. Randomized comparison to alendronate

Journal of Bone and Mineral Research, 08/20/2013

Preclinical studies indicate that strontium ranelate (SrRan) induces opposite effects on bone osteoblasts and osteoclasts, suggesting that SrRan may have a dual action on both formation and resorption. By contrast, alendronate (ALN) is a potent antiresorptive agent. This large controlled paired–biopsy study over one year shows that the bone formation remains higher with a lower diminution of the bone remodeling with SrRan versus ALN. From these results SrRan did not show a significant anabolic action on bone remodeling.

Print Article Summary Cat 2 CME Report